The analyst suggested a stoploss at Rs 296.

Sell Biocon Ltd. at a price target of Rs 205.0 and a stoploss at Rs 222 from entry point.

Sell Biocon Ltd. at a price target of Rs 208.0 and a stoploss at Rs 222 from entry point.

Sell Biocon Ltd. at a price target of Rs 206.0 and a stoploss at Rs 224 from entry point.

Buy Biocon Ltd. at a price target of Rs 634.0 and a stoploss at Rs 608 from entry point.

Sell Biocon Ltd. at a price target of Rs 590.0 and a stoploss at Rs 616 from entry point.

Buy Biocon Ltd. at a price target of Rs 682.0 and a stoploss at Rs 658 from entry point.

Buy Biocon Ltd. at a price target of Rs 650.0 and a stoploss at Rs 620 from entry point.

Buy Biocon Ltd. at a price target of Rs 706.0 and a stoploss at Rs 668 from entry point.

Buy Biocon Ltd. at a price target of Rs 660.0 and a stop loss at Rs 630 from the entry point.

Buy Biocon Ltd. at a price target of Rs 625.0 and a stop loss at Rs 594 from entry point.

Buy Biocon Ltd. at a price target of Rs 668.0 and a stop loss at Rs 622 from entry point.

Buy Biocon Ltd. at a price target of Rs 642.0 and a stop loss at Rs 606 from entry point.

Buy Biocon Ltd. at a price target of Rs 641.0 and a stop loss at Rs 620 from entry point.

Buy Biocon at a price target of Rs 380 and a stop loss at Rs 363 from entry point.

Natco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug,...

Teva Pharmaceutical Industries Ltd named Jeremy Levin of Bristol-Myers Squibb Coto to replace Shlomo Yanai as chief executive officer.